InMode Ltd.

InMode Ltd.

INMD
InMode Ltd.US flagNASDAQ Global Select
15.41
USD
+0.33
(+2.16%)
2.25EPS
6.85P/E
1.07BMarket Cap
Apr 28Next Earn
Capital Structure

in mil. unless spec.
Working Capital

in mil. unless spec.
Growth Rates

in mil. unless spec.
Quarterly Revenue

in mil. unless spec.
Quarterly Earnings Per Share

in mil. unless spec.
Quarterly Dividends Per Share

in mil. unless spec.

Company Description

CEO
Mr. Moshe Mizrahy
Full Time Employees
599
Sector
Healthcare
Industry
Medical - Devices
Address
Tavor Building Yokne'am Israel 2069206
IPO Date
Aug 8, 2019
Similar Companies
Business
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokneam, Israel.

Company News

  • InMode (INMD) Soars 6.8%: Is Further Upside Left in the Stock?

  • InMode: Strategic Capital Allocation Unlocks Shareholder Value (Rating Upgrade)

  • 3 Undervalued MedTech Stocks to Buy for 2025 Gains Amid S&P 500 Rally

  • InMode to Present at the 24th Annual Needham Virtual Healthcare Conference

  • Is InMode (INMD) Stock Undervalued Right Now?

  • InMode Responds to Doma Perpetual's Letters

  • InMode to Present at Upcoming Investor Conferences

  • InMode: Plastic Surgery Boom, Cash Flow, And Cheap

  • InMode Ltd. (INMD) Q4 2024 Earnings Call Transcript

  • InMode Reports Fourth Quarter and Full Year 2024 Financial Results; Board of Directors Has Approved a New Share Repurchase Program

  • InMode to Participate in the BTIG MedTech, Digital Health, Life Sciences & Diagnostics Tools Conference

  • InMode: A Clear Bargain With Unique Risks

  • InMode to Report Fourth Quarter & Full Year 2024 and Hold Conference Call on February 4, 2025, Earlier than Originally Announced

  • DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Immediately Execute Tender Offer followed by Share Buyback

  • InMode: Clearly, I Was Too Optimistic (Rating Downgrade)

  • InMode to Report Fourth Quarter & Full Year 2024 Financial Results and Hold Conference Call on February 6, 2025, Expects Q4 Revenue Between $97.0M-$97.5M

  • InMode: Product Origination And Undervaluation Make The Stock A Buy

  • InMode to Present at Upcoming Investor Conferences

  • InMode: $25/Share Is Closer Than You Think

  • InMode: A Deep Dive After Q3 Earnings